CG Oncology, Company Leadership
| CGON Stock | 34.75 0.65 1.91% |
CG Oncology, employs about 61 people. The company is managed by 8 executives with a total tenure of roughly 143 years, averaging almost 17.0 years of service per executive, having 7.63 employees per reported executive. Analysis of CG Oncology,'s management performance can provide insight into the firm performance.
CGON |
CG Oncology, Management Team Effectiveness
The company has return on total asset (ROA) of (0.157) % which means that it has lost $0.157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1976) %, meaning that it created substantial loss on money invested by shareholders. CG Oncology,'s management efficiency ratios could be used to measure how well CG Oncology, manages its routine affairs as well as how well it operates its assets and liabilities.CG Oncology, Workforce Comparison
CG Oncology, Common is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 41,622. CG Oncology, adds roughly 61.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CG Oncology, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CG Oncology, insiders, such as employees or executives, is commonly permitted as long as it does not rely on CG Oncology,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CG Oncology, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corleen Roche over three weeks ago Acquisition by Corleen Roche of 93600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Song Hong Fang over a month ago Acquisition by Song Hong Fang of 15600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Decheng Capital Global Life Sciences Fund Iv Lp over six months ago Conversion by Decheng Capital Global Life Sciences Fund Iv Lp of 3628198 shares of CG Oncology, | ||
Bellete Ambaw over six months ago CG Oncology exotic insider transaction detected |
CG Oncology, Notable Stakeholders
A CG Oncology, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CG Oncology, often face trade-offs trying to please all of them. CG Oncology,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CG Oncology,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Arthur Kuan | Chairman CEO | Profile | |
| Ambaw MS | President COO | Profile | |
| Corleen Roche | CFO Secretary | Profile | |
| Bing Kung | Vice Development | Profile | |
| Joshua Patterson | General Officer | Profile | |
| Swapnil Bhargava | Chief Officer | Profile | |
| Vijay MD | Chief Officer | Profile | |
| Amy Steele | Accounting Finance | Profile |
About CG Oncology, Management Performance
The success or failure of an entity such as CG Oncology, Common often depends on how effective the management is. CG Oncology, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CGON management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CGON management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CG Oncology, Workforce Analysis
Traditionally, organizations such as CG Oncology, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CG Oncology, within its industry.CG Oncology, Manpower Efficiency
Return on CG Oncology, Manpower
| Revenue Per Employee | 3.3K | |
| Revenue Per Executive | 25.5K | |
| Net Loss Per Employee | 796.8K | |
| Net Loss Per Executive | 6.1M | |
| Working Capital Per Employee | 2.9M | |
| Working Capital Per Executive | 22.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.